Approach to identifying and managing ICI related toxicities
Event DetailsEvent Details
The main aim of this webinar is to educate our audience about common and rare but severe toxicities related to the use of PD-1 inhibitors. This webinar is part of a series of webinars with a focus on immune checkpoint inhibitors, with an emphasis on education around the benefits and indications for immunotherapy, the identification and management of adverse events, and on team building for safe treatment delivery.
Describe common and rare toxicities related to PD-1 inhibitors (ICI)
Identify ICI toxicities including monitoring
Understand management pathways for the treatment of ICI toxicities
Dr Susana Banerjee MBBS MA PhD FRCP is a Consultant Medical Oncologist and Research Lead for the Gynaecology Unit. She is also Reader in Women’s Cancers at the Institute of Cancer Research. Dr Banerjee specialises in ovarian cancer and the systemic treatment of endometrial and cervical cancers.
Dr Banerjee graduated with a 1st class from St John’s College, University of Cambridge, and completed her medical training at Royal Free Medical School where she was a University of London Gold Medal finalist. Dr Banerjee gained a PhD from The Institute of Cancer Research, University of London and was awarded the San Antonio Breast Cancer Symposium Novartis Oncology Basic Science Award for her research. Other prizes include the Association of Cancer Physicians McElwain Prize, the Sir Antony Driver Prize and the Pfizer British Oncology Association Young Investigator Award (highly commended).
Dr Banerjee has served in international specialist groups including the European Organization for Research and Treatment of Cancer (EORTC) Executive Steering Committee for Gynaecological Cancers, ESGO (European Society of Gynaecological Oncology) Congress Faculty and International Gynecologic Cancer Society Scientific Program Committee. Dr Susana Banerjee was elected to be part of the European Society of Medical Oncology (ESMO) Executive Board as Director of Membership (2020-2022) and chairs the ESMO Resilience Task Force. She was Track Chair for Gynaecological Cancers for the ESMO Congress 2018, Scientific Co-Chair for ESMO Asia 2018 and Co-Chair of the ESMO Gynaecological Cancers Congress 2021 and 2022.
Dr Banerjee is an author of over 170 peer-reviewed publications including in the New England Journal of Medicine, Lancet, Lancet Oncology, Journal of Clinical Oncology and Annals of Oncology. Her research interests include individualisation of patient treatment, targeted therapies (including PARP inhibitors) and rare gynaecological cancers. Dr Banerjee has Global and UK Chief Investigator roles of multiple national and international clinical trials.
WHO WE ARE
Fueled by our human health care mission, we’re an inspired team of innovators relentlessly pursuing ways to improve the lives of patients and their families.
WHAT IS human health care?
It's our way of life at Eisai — giving our first thought to patients and their families. Doing so drives us to create breakthrough solutions and medicines for them.
HOW WE BRING human health care TO LIFE
Breakthrough medicines are just the beginning. human health care sparks a multitude of ways in which we improve the lives of patients, their families and caregivers.
IT’S ONE THING TO TALK ABOUT PUTTING PATIENTS FIRST. IT’S QUITE ANOTHER TO DO IT FOR MORE THAN THREE DECADES.
Eisai came to America in 1987 with one goal in mind: Create innovative new medicines to help patients, their families and caregivers. In 2011, Eisai Canada joined in pursuing this goal. We’ve been breaking through ever since, with solutions and therapies that help improve the lives of the people we serve.
How does human health care lead to breakthrough products? The key is understanding the true needs of patients. We know in our hearts how the possibility of a breakthrough can help patients and their families keep fighting. That's why we keep fighting to discover and develop solutions.
For more information, please visit our website at www.eisai.ca
To make a difference in the lives of people through our innovative medicines, vaccines, and animal health products. We are committed to being the premier, research-intensive biopharmaceutical company and are dedicated to providing leading innovations and solutions for today and the future.